Clinical Trial Update: Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial reports results for a long-acting injectable form of risperidone in patients with schizophrenia after an acute episode.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Risperidone long-acting injectable (risperidone)

Snippet

Sponsor: Janssen Pharmaceutica N.V., Belgium | Conditions: Schizophrenia | Phase 4 | Status: COMPLETED | Results posted: 2011-12-02